Table 3 Phase 2: Self-reported clinical characteristics
From: Understanding side effects of therapy for myasthenia gravis and their impact on daily life
Characteristic | Overall Sample (N = 242) n (%) |
|---|---|
In which of the following areas have you ever experienced myasthenia gravis symptoms?1 | |
 Eye muscles | 218 (90.1%) |
 Chewing, swallowing, speaking | 206 (85.1%) |
 Neck, arm, and legs | 198 (81.8%) |
 Breathing | 149 (61.6%) |
 Other | 42 (17.4%) |
In the past month, where have you experienced myasthenia gravis symptoms?1 | |
 Eye muscles | 150 (62.0%) |
 Chewing, swallowing, speaking | 139 (57.4%) |
 Neck, arm, and legs | 137 (56.6%) |
 Breathing | 87 (36.0%) |
 Other | 50 (20.7%) |
Current medication(s)/procedures for myasthenia gravis1 | |
 Pyridostigmine | 167 (69.0%) |
 Oral corticosteroids | 82 (33.9%) |
 Mycophenolate mofetil | 61 (25.2%) |
 Intravenous immunoglobulin (IVIg) | 57 (23.6%) |
 Azathioprine | 52 (21.5%) |
 Plasma exchange | 14 (5.8%) |
 Rituximab | 13 (5.4%) |
 Methotrexate | 7 (2.9%) |
 Cyclophosphamide | 1 (0.4%) |
 Tacrolimus | 1 (0.4%) |
 Other | 21 (8.7%) |
 None | 15 (6.2%) |
Medication(s) ever taken for myasthenia gravis1 | |
 Oral corticosteroids | 101 (41.7%) |
 Pyridostigmine | 99 (40.9%) |
 Intravenous immunoglobulin (IVIg) | 73 (30.2%) |
 Azathioprine | 65 (26.9%) |
 Plasma exchange | 57 (23.6%) |
 Mycophenolate mofetil | 55 (22.7%) |
 Rituximab | 15 (6.2%) |
 Cyclosporine A | 11 (4.5%) |
 Methotrexate | 7 (2.9%) |
 Neostigmine | 6 (2.5%) |
 Cyclophosphamide | 3 (1.2%) |
 Other | 9 (3.7%) |
 None | 41 (16.9%) |
Previous thymectomy (% yes) | 91 (37.6%) |